Scholarlink

<p>In March 2023 and 2024, a panel of international experts convened at the first and second Intercepting Blood Cancers (IBC) Workshops, with the aim of better appreciating the diagnostic challenges, pathophysiology, and potential therapeutic interventions for precursor malignant hematology conditions. Here, we report a summary of the proceedings from the sessions focused on monoclonal B-cell lymphocytosis (MBL)/chronic lymphocytic leukemia (CLL). We highlight four main content areas: biology of MBL, clinical implications of MBL, progression of MBL and transformation from indolent CLL to aggressive disease, and opportunities for therapeutic intervention in early CLL. We additionally outline key consensus management recommendations and research goals.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月29日

查看全文
  • Christine E. Ryan,
  • Inhye E. Ahn,
  • Aswin Sekar,
  • Andrew Rawstron,
  • Julia Almeida,
  • Iñaki Martin-Subero,
  • Erin M. Parry,
  • Miguel Alcoceba,
  • Dinis P. Calado,
  • Alberto Orfao,
  • Anton W. Langerak,
  • Hendrik Veelken,
  • Petra Langerbeins,
  • Deborah M. Stephens,
  • Sameer A. Parikh,
  • Carsten U. Niemann,
  • Sandrine Roulland,
  • Kostas Stamatopoulos,
  • Susan L. Slager,
  • Tait Shanafelt,
  • Paolo Ghia,
  • Jessica Okosun,
  • Matthew S. Davids

摘要

In March 2023 and 2024, a panel of international experts convened at the first and second Intercepting Blood Cancers (IBC) Workshops, with the aim of better appreciating the diagnostic challenges, pathophysiology, and potential therapeutic interventions for precursor malignant hematology conditions. Here, we report a summary of the proceedings from the sessions focused on monoclonal B-cell lymphocytosis (MBL)/chronic lymphocytic leukemia (CLL). We highlight four main content areas: biology of MBL, clinical implications of MBL, progression of MBL and transformation from indolent CLL to aggressive disease, and opportunities for therapeutic intervention in early CLL. We additionally outline key consensus management recommendations and research goals.